Drug Treatments for Leading Endocrine and Metabolic Diseases
The global market for prescription endocrine and metabolic disease drugs was $66.2 billion in 2005 and $72.3 billion in 2006. At a compounded annual growth rate (CAGR) of 5.2%, the market will reach $96.4 billion by 2011.
Drugs for hypercholesterolemia dominated the highest share of the market, worth almost $37.1 billion in 2006, a 51.3% share. By 2011 its share will drop slightly to 47.2% ($45.5 billion of the total market), though it will remain the largest sector of the market.
Obesity drugs and treatment have the highest growth potential throughout the forecast period. A relatively small market, its growth however is booming at a CAGR of 23.8%. By 2011 the sector will be worth more than $4.0 billion.
The aim of this report is to provide a range of information - from detailed market analyses through industry trends - to quantify, qualify, and compare prescription products on the market and in development for the treatment of selected endocrine and metabolic disorders. There is a correlation between several endocrine and metabolic disorders, and recently there has been considerable emphasis put on metabolic syndrome, which comprises several interrelated endocrine and metabolic disorders. The metabolic components of cardiovascular disease and obesity, for example, are linked in numerous ways that reflect the impact each has on the other. Reduction in obesity reduces the incidence of diabetes, and both of these conditions, independently, are major contributors to cardiovascular disease.
SCOPE OF STUDY
This report contains:
- The major current and emerging markets for prescription drugs for endocrine and metabolic diseases, including hypertension, infertility, thyroid diseases, hypercholesterolemia, and obesity
- Historical market data from 2004, 2005, and 2006, in addition to five-year market forecasts with compounded annual growth rates through 2011
- Discusses applications as well as current and upcoming technology and trends
- Provides detailed patent analysis and profiles of the major companies in the biotechnology and pharmaceutical industries that provide products for the diseases covered in this report.
The base year for this study is 2006. Figures are based on revenue figures at the manufacturer's level and are projected at 2006 dollar value - that is, inflation is not computed into the projection figures.
Data and trends obtained to prepare this study were derived from information obtained from pharmaceutical product managers, marketing strategists, research executives, and others at leading biotechnology and pharmaceutical companies that have products used in the treatment of the diseases covered in this report, or which have products in development for these markets.
The information and analyses presented in this report are based on an extensive survey of the pharmaceutical industries, as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations, and national and world health organizations. Key information from the business literature was used to obtain expert opinion on commercial potential and market sizes from industry professionals.
ABOUT THE AUTHOR
Lynn Gray has been a research analyst in the biotechnology and life sciences area since 1989. Her collaboration with BCC Research began in 1996, and since then she has authored over 20 BCC biomedical reports